Chris Garabe­di­an's Xon­toge­ny shep­herds two more com­pa­nies through $60M Se­ries A rounds

Xon­toge­ny CEO Chris Garabe­di­an un­veiled two rounds of Se­ries A fi­nanc­ing on Tues­day: one for Tel­lus Ther­a­peu­tics, a neona­tal care com­pa­ny, and an­oth­er for Per­ox­itech, a bio­phar­ma work­ing on a pep­tide for treat­ing acute lung in­jury.

The $35 mil­lion Se­ries A round for Tel­lus Ther­a­peu­tics and the $25 mil­lion for Per­ox­itech will bring the com­pa­nies through ear­ly clin­i­cal tri­als for two new drugs, in­clud­ing work that al­lows them to sub­mit an ap­pli­ca­tion to the FDA to con­duct tri­als. The rounds come from the Per­cep­tive Xon­toge­ny Ven­ture Fund, which Garabe­di­an runs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER